In the past few months patients diagnosed with Hepatitis C have seen what had been terminal conditions be cured. The technology used to find these curative treatments can now be applied to other conditions.
"How do you move a glacier?" asked Lawrence Kosinski, MD, MBA, AGAF, FACG, managing partner of Illinois Gastroenterology Group (IGG) at the 2015 AGA Clinical Congress of Gastroenterology and Hepatology.
“There are only 2 or 3 things I know for sure. Only 2 or 3 things. That’s right. Of course, it’s never the same things, and I’m never as sure as I’d like to be,” nuggets of wisdom (from the novel "Bastard Out of Carolina," by Dorothy Allison) that Thomas Murray, Senior Director of Quality Measurement & Improvement, AGA, shared at the 2015 AGA Clinical Congress of Gastroenterology & Hepatology.
If all goes as planned, Merck will soon take a major step forward in the hot pursuit among pharmaceutical companies to produce a newer, better, faster-working drug to treat the millions of people who have chronic hepatitis C infection.
A recent clinical trial, published in The Lancet, involving a 6-week course of a combination of 3 direct-acting oral drugs was found to cure 38 of 40 individuals with hepatitis C virus infection (HCV).
Following 2 recent studies published in Gastroenterology, researchers reported that a 24-week course of sofosbuvir and ribavirin could eliminate hepatitis C virus (HCV) infection in two-thirds of patients who undergo liver transplantation.